Toumeh Anis, Sakhi Ramen, Shah Sarthi, Arudra Sri Krishna Chaitanya, De Las Casas Luis E, Skeel Roland T
Department of Internal Medicine, Division of Medical Oncology and Department of Pathology, The University of Toledo Medical Center, Toledo, OH.
Am J Ther. 2016 Jul-Aug;23(4):e1068-71. doi: 10.1097/MJT.0000000000000266.
Malignant melanoma is the most aggressive cutaneous malignancy with dismal prognosis in the advanced setting. The food and drug administration approval of ipilimumab, the monoclonal antibody against cytotoxic T-lymphocyte antigen 4, has significantly changed treatment strategies for this disease. However, the spectrum of immune-related adverse events secondary to ipilimumab therapy is a growing area of research, and clinical observations of rare immune events as a result of such therapies continue to be reported since the approval. The co-occurrence of disease progression along with an immune-related adverse event is extremely rare. We here present the first case, to our knowledge, of diffuse nonnecrotizing granulomatous lymphadenopathy occurring simultaneously with disease progression in a patient with metastatic melanoma after receiving the second dose of ipilimumab.
恶性黑色素瘤是最具侵袭性的皮肤恶性肿瘤，在晚期情况下预后不佳。抗细胞毒性T淋巴细胞抗原4单克隆抗体伊匹单抗获得美国食品药品监督管理局批准，显著改变了该疾病的治疗策略。然而，伊匹单抗治疗继发的免疫相关不良事件范围是一个不断发展的研究领域，自批准以来，此类治疗导致罕见免疫事件的临床观察仍不断有报道。疾病进展与免疫相关不良事件同时出现极为罕见。据我们所知，本文首次报道了1例转移性黑色素瘤患者在接受第二剂伊匹单抗后，疾病进展同时发生弥漫性非坏死性肉芽肿性淋巴结病的病例。
